来氟米特治疗系统性红斑狼疮的临床疗效及对血清BAFF MCP-4 IL-8 IL-10水平的影响

doi:10.3969/j.issn.1006-6233.2018.12.006

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (1356 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the clinical efficacy and safety of leflunomide in the treatment of systemic lupus erythematosus (SLE) and its effects on serum levels of B cell activating factor (BAFF), monocyte chemoattractant protein (MCP-4), interleukin-8 (IL-8) and interleukin-10 (IL-10). Methods: 96 patients with systemic lupus erythematosus admitted to our hospital from September 2014 to September 2016 were selected. According to the simple random number table, all the patients were divided into the observation group (n=48) and the control group (n=48). The control group was treated with glucocorticoid, while the observation group was treated with leflunomide. Then the clinical effect, the changes of 24 h urinary protein, SLEDAI scores, serum levels of BAFF, MCP-4, IL-8 and IL-10, and the incidence of adverse reactions in the two groups before and after treatment were observed and compared between the two groups. Results: After treatment, the total effective rate of observation group was significantly higher than that of the control group (P＜0.05). Before treatment, there was no significant difference in the 24h urinary protein, SLEDAI score, serum BAFF, MCP-4, IL-8 and IL-10 levels between the two groups (P＞0.05); after treatment, the 24h urinary protein, SLEDAI score, serum BAFF, MCP-4, IL-8 and IL-10 of the two groups were significantly improved compared to those before treatment (P＜0.05), the 24h urinary protein, SLEDAI scores, serum BAFF, MCP-4, IL-8 and IL-10 levels of observation group were significantly lower than those of the control group (P＜0.05); the incidence of adverse reactions in the observation group was significantly lower than that of the control group (P＜0.05). Conclusion: Leflunomide can enhance the clinical efficacy in the treatment of systemic lupus erythematosus, which may be related to the inhibition of serum BAFF, MCP-4, IL-8 and IL-10 levels.

Key words： Systemic lupus erythematosus Leflunomide B cell activating factor Monocyte chemotaxis protein-4 Interleukin-8 interleukin-10

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.12.006 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I12/1957

[1] Suarez H F, Urrutia E D, Canales P F, et al. Neuromyelitis optica presenting concomitantly with systemic lupus erythematosus: report of one case[J].Rev Med Chil, 2016, 144(9): 1226~1229.
[2] 张静,张蓓蓓,蔡辉.系统性红斑狼疮发病机制和生物学标志物的研究进展[J].现代医学,2017,45(6):887~890.
[3] Park SK, Park SH, Lee MY, et al. Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with patent expiration in South Korea[J]. Clin Ther, 2016, 38(11): 2430~2446.
[4] Ge XY, Shao L, Zheng ZL. Assessment right atrial function in patients with systemic lupus erythematosus by speckle tracking and three-dimensional echocardiography[J]. National Medical Journal of China, 2016, 96(47): 3815~3818.
[5] Nishino A,Hanaoka M,Katsumata Y, et al.Technetium-99m Albumin Scintigraphy in Protein-Losing Gastroenteropathy With Systemic Lupus Erythematosus: Typical Diagnostic Pattern of Radiotracer Leakage and Chronological Improvement by Treatment[J].Clin Rheumatol, 2017, 23(1): 41~42.
[6] Gao YH,Li SQ, Yang C, et al.Multifocal osteonecrosis in an adolescent patient with systemic lupus erythematosus and ankle pain[J].Clin Rheumatol, 2017, 23(1): 40.
[7] Han GM, Han XF. Comorbid conditions are associated with emergency department visits, hospitalizations, and medical charges of patients with systemic lupus erythematosus[J].Clin Rheumatol, 2017, 23(1): 19~25.
[8] Hodkinson B, Magomero KR, Tikly M. Combination leflunomide and methotrexate in refractory rheumatoid arthritis: a biologic sparing approach[J]. Ther Adv Musculoskelet Dis, 2016, 8(5): 172~179.
[9] 张春华.甲氨蝶呤与来氟米特治疗类风湿性关节炎的临床疗效和安全性研究[J].重庆医学,2015,44(4):511~513.
[10] Wu J, Duan SW, Sun XF, et al. Efficacy of leflunomide, telmisartan and clopidogrel for immunoglobulin a nephropathy: a randomized controlled trial[J].Chin Med (Engl), 2016, 129(16): 1894~1903.
[11] Mohammad LA, Atef DM, Abul-Saoud AM. Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients[J].Hum Immunol, 2015, 76(10): 724~728.
[12] 崔员霞,江峰,付朝伟,等.BAFF基因多态性与系统性红斑狼疮相关性的Meta分析[J].免疫学杂志,2015,31(6):505~511.
[13] 余静,马玲.环磷酰胺联合人免疫球蛋白治疗系统性红斑狼疮的疗效及其对患者血清MCP-4和IL-4的影响[J].海南医学,2015,26(2):175~177.
[14] Aerbajinai W, Liu L, Zhu J, et al. Glia maturation factor-γ regulates monocyte migration through modulation of β1-integrin[J].Biol Chem, 2016, 291(16): 8549~8564.